Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

PURPOSE: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A. EXPERIMENTAL DESIGN: Patients with locally advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Juric, Dejan, Dienstmann, Rodrigo, Cervantes, Andres, Hidalgo, Manuel, Messersmith, Wells, Blumenschein, George R., Tabernero, Josep, Roda, Desamparados, Calles, Antonio, Jimeno, Antonio, Wang, Xiaodong, Bohórquez, Sandra Sanabria, Leddy, Cecilia, Littman, Catherine, Kapp, Amy V., Shames, David S., Penuel, Elicia, Amler, Lukas C., Pirzkall, Andrea, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705193/
https://ncbi.nlm.nih.gov/pubmed/26034219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados